EU approved AstraZeneca’s Forxiga for heart failure

The FINANCIAL — AstraZeneca’s Forxiga (dapagliflozin) has been approved in the European Union (EU) for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF) in adults with and without type-2 diabetes (T2D). Heart failure (HF) is a life-threatening chronic disease that

More
4 mins read
1 2 3 195